SynthesisBMC infectious diseases2023
Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants.
Synthesis in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Risk of SARS-CoV-2 Transmission in Community Indoor Settings: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2024Pooled it
- Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis.BMC medicine · 2023Pooled it
- Generation time in a discrete epidemic model with asymptomatic carriers: beyond geometric waiting times.Infectious Disease Modelling · 2027Article
- A systematic comparison of methodologies for the estimation of the serial interval.Infectious Disease Modelling · 2026Article
- Viral genotype and the pace of epidemic waves: an assessment from SARS-CoV 2 genomics and wastewater surveillance data.Archives of virology · 2026Article
- VIBES: A multiscale modeling approach integrating within-host and between-hosts dynamics in epidemics.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Household Transmission of COVID-19 and Influenza During the Early Omicron Era: An Insurance Claims Database Study in Japan.Viruses · 2026Article
- Article
- Belgium's SARS-CoV-2 contact tracing effectively curbed transmission, yet challenges persist in terms of delays, scalability and population adherence.BMC public health · 2025Article
- Epidemiological indices with multiple circulating pathogen strains.Infectious Disease Modelling · 2025Article
- SARS-CoV-2 secondary attack rates and risks for transmission among agricultural workers and their households in Guatemala, 2022-2023.IJID regions · 2025Article
- Nonparametric serial interval estimation with uniform mixtures.PLoS computational biology · 2025Article
- Seasonal synchronization and unpredictability in epidemic models with waning immunity and healthcare thresholds.Scientific reports · 2025Article
- A protein language model for exploring viral fitness landscapes.Nature communications · 2025Article
- Article
- The importance of playing the long game when it comes to pandemic surveillance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Effect of the renin-angiotensin-aldosterone system inhibitors on time to nucleic acid negative conversion in hypertensive patients with SARS-CoV-2 omicron infection: a propensity score matching study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Observational
- The SARS-CoV-2 test scale-up in the USA: an analysis of the number of tests produced and used over time and their modelled impact on the COVID-19 pandemic.The Lancet. Public health · 2025Article
- Jing Guan Fang, an herbal formula, as an immunomodulator: opposing effects on basal and lipopolysaccharide-induced inflammation of macrophage via JAK/STAT3 and MAPK pathways.Frontiers in pharmacology · 2025Article
- Epidemiological impact of revoking mask-wearing recommendation on COVID-19 transmission in Tokyo, Japan.Infectious Disease Modelling · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe serial interval is the period of time between symptom onset in the primary case and symptom onset in the secondary case. Understanding the serial interval is important for determining transmission dynamics of infectious diseases like COVID-19, including the reproduction number and secondary attack rates, which could influence control measures. Early meta-analyses of COVID-19 reported serial intervals of 5.2 days (95% CI: 4.9-5.5) for the original wild-type variant and 5.2 days (95% CI: 4.87-5.47) for Alpha variant. The serial interval has been shown to decrease over the course of an epidemic for other respiratory diseases, which may be due to accumulating viral mutations and implementation of more effective nonpharmaceutical interventions. We therefore aggregated the literature to estimate serial intervals for Delta and Omicron variants.
methodsThis study followed Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. A systematic literature search was conducted of PubMed, Scopus, Cochrane Library, ScienceDirect, and preprint server medRxiv for articles published from April 4, 2021, through May 23, 2023. Search terms were: ("serial interval" or "generation time"), ("Omicron" or "Delta"), and ("SARS-CoV-2" or "COVID-19"). Meta-analyses were done for Delta and Omicron variants using a restricted maximum-likelihood estimator model with a random effect for each study. Pooled average estimates and 95% confidence intervals (95% CI) are reported.
resultsThere were 46,648 primary/secondary case pairs included for the meta-analysis of Delta and 18,324 for Omicron. Mean serial interval for included studies ranged from 2.3-5.8 days for Delta and 2.1-4.8 days for Omicron. The pooled mean serial interval for Delta was 3.9 days (95% CI: 3.4-4.3) (20 studies) and Omicron was 3.2 days (95% CI: 2.9-3.5) (20 studies). Mean estimated serial interval for BA.1 was 3.3 days (95% CI: 2.8-3.7) (11 studies), BA.2 was 2.9 days (95% CI: 2.7-3.1) (six studies), and BA.5 was 2.3 days (95% CI: 1.6-3.1) (three studies).
conclusionsSerial interval estimates for Delta and Omicron were shorter than ancestral SARS-CoV-2 variants. More recent Omicron subvariants had even shorter serial intervals suggesting serial intervals may be shortening over time. This suggests more rapid transmission from one generation of cases to the next, consistent with the observed faster growth dynamic of these variants compared to their ancestors. Additional changes to the serial interval may occur as SARS-CoV-2 continues to circulate and evolve. Changes to population immunity (due to infection and/or vaccination) may further modify it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.